An interdependence between GAPVD1 gene polymorphism, expression level and response to interferon beta in patients...

Area of Science:

• Neuroimmunology
• Pharmacogenetics

Background:

• Interferon-beta (IFN-β) is a first-line treatment for multiple sclerosis (MS).
• Patient genetic predisposition may influence therapeutic efficacy of IFN-β.
• Understanding genetic markers can personalize MS treatment.

Purpose of the Study:

• To investigate the association between GAPVD1 gene expression, the rs2291858 polymorphism, and patient response to IFN-β in multiple sclerosis.
• To identify potential biomarkers for predicting IFN-β treatment outcomes in MS patients.

Main Methods:

• Gene expression analysis of GAPVD1 in 100 responder and 100 non-responder MS patients treated with IFN-β.
• Genotyping of the rs2291858 variant in 200 MS patients (responders and non-responders) and 200 healthy controls.
• Statistical analysis to compare gene expression levels and genotype distributions between groups.

Main Results:

• Significantly higher GAPVD1 expression was observed in IFN-β responder patients compared to non-responders.
• The distribution of the rs2291858 polymorphism differed significantly between responder and non-responder groups.
• The AA genotype of rs2291858 showed higher GAPVD1 expression in responders than in other genotypes across both groups.

Conclusions:

• GAPVD1 gene expression levels and the rs2291858 genotype are likely factors influencing IFN-β treatment response in multiple sclerosis.
• These findings suggest potential genetic biomarkers for predicting therapeutic outcomes in MS patients.
• Further research is warranted to validate these genetic associations for clinical application.